

Chigusa Morizane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5535310/publications.pdf>

Version: 2024-02-01

186
papers

5,138
citations

94433

37
h-index

110387

64
g-index

190
all docs

190
docs citations

190
times ranked

6823
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. <i>Scientific Reports</i> , 2022, 12, 987.	3.3	3
2	Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. <i>Cancer Discovery</i> , 2022, 12, 692-711.	9.4	58
3	Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 134-142.	1.3	5
4	Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreatic cancer syndrome: The Diamond Study. <i>Pancreatology</i> , 2022, , .	1.1	5
5	Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 716-724.	1.3	6
6	Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. <i>Future Oncology</i> , 2022, 18, 2351-2360.	2.4	22
7	Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). <i>Oncologist</i> , 2021, 26, 97-e201.	3.7	2
8	Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). <i>Journal of Gastroenterology</i> , 2021, 56, 250-260.	5.1	31
9	Precision Medicine for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 171-184.		0
10	Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma. <i>Pancreas</i> , 2021, 50, 77-82.	1.1	12
11	Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases. <i>American Journal of Surgical Pathology</i> , 2021, 45, 616-626.	3.7	27
12	A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus Sâ€ versus placebo plus Sâ€ in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. <i>Cancer Medicine</i> , 2021, 10, 2088-2099.	2.8	1
13	Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS). <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 489-497.	2.6	8
14	Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. <i>Immunotherapy</i> , 2021, 13, 371-385.	2.0	16
15	Fibroblast growth factor receptor 2 (<i>FGFR2</i>) fusions in Japanese patients with intrahepatic cholangiocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 911-917.	1.3	3
16	Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1185-1196.	1.3	8
17	Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas. <i>Pancreatology</i> , 2021, 21, 738-745.	1.1	4
18	Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. <i>Scientific Reports</i> , 2021, 11, 12885.	3.3	1

#	ARTICLE	IF	CITATIONS
19	MO38-3 Clinical update with genomic analyses in expansion part of phase 1 study of selective FGFR inhibitor E7090. <i>Annals of Oncology</i> , 2021, 32, S324.	1.2	0
20	A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2065-2072.	2.2	5
21	JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. <i>Journal of Gastroenterology</i> , 2021, 56, 1033-1044.	5.1	58
22	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 348-348.	1.6	0
23	FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 397-404.	2.3	5
24	Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113.. <i>Journal of Clinical Oncology</i> , 2021, 39, 301-301.	1.6	1
25	Clinical Characteristics of Pancreatic and Biliary Tract Cancers Associated with Lynch Syndrome. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, , .	2.6	4
26	Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study. <i>BMC Cancer</i> , 2020, 20, 946.	2.6	10
27	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	30.7	209
28	Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. <i>BMC Cancer</i> , 2020, 20, 1105.	2.6	50
29	Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. <i>Pancreatology</i> , 2020, 20, 1421-1427.	1.1	18
30	Hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study. <i>BMJ Open</i> , 2020, 10, e038276.	1.9	3
31	O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 2469.	3.7	26
32	Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. <i>Human Pathology</i> , 2020, 105, 9-19.	2.0	15
33	Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). <i>International Journal of Clinical Oncology</i> , 2020, 25, 1835-1843.	2.2	6
34	Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. <i>Pancreatology</i> , 2020, 20, 944-950.	1.1	14
35	Novel endoscopic technique for trisegment drainage in patients with unresectable hilar malignant biliary strictures (with video). <i>Gastrointestinal Endoscopy</i> , 2020, 92, 763-769.	1.0	7
36	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. <i>Cancer Treatment Reviews</i> , 2020, 86, 101998.	7.7	25

#	ARTICLE	IF	CITATIONS
37	Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	15
38	Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms. <i>Current Drug Targets</i> , 2020, 21, 389-405.	2.1	1
39	Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. <i>Investigational New Drugs</i> , 2019, 37, 109-117.	2.6	20
40	Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. <i>Internal Medicine</i> , 2019, 58, 2435-2441.	0.7	4
41	Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 611-621.	8.1	223
42	Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer. <i>Annals of Oncology</i> , 2019, 30, vi86-vi87.	1.2	0
43	Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. <i>Annals of Oncology</i> , 2019, 30, 1950-1958.	1.2	195
44	Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 561.	4.1	32
45	Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 301.	2.8	1
46	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019, 110, 1480-1490.	3.9	238
47	Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. <i>Annals of Surgical Oncology</i> , 2019, 26, 1385-1393.	1.5	36
48	Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer. <i>Annals of Oncology</i> , 2019, 30, vi86.	1.2	0
49	A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1073-1082.	1.3	12
50	First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 507-518.	2.6	16
51	A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 306-306.	1.6	4
52	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring <i>FGFR2</i> gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS468-TPS468.	1.6	6
53	Germline mutations in cancer-predisposition genes in patients with biliary tract cancer. <i>Oncotarget</i> , 2019, 10, 5949-5957.	1.8	9
54	Familial Pancreatic Cancer and Surveillance of High-Risk Individuals. <i>Gut and Liver</i> , 2019, 13, 498-505.	2.9	18

#	ARTICLE	IF	CITATIONS
55	The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113.. Journal of Clinical Oncology, 2019, 37, 349-349.	1.6	0
56	The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113.. Journal of Clinical Oncology, 2019, 37, 368-368.	1.6	0
57	Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology, 2018, 48, 103-114.	1.3	192
58	Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Journal of Gastroenterology, 2018, 53, 1159-1167.	5.1	7
59	Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment. Oncology, 2018, 94, 72-78.	1.9	11
60	Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Cancer Science, 2018, 109, 215-224.	3.9	39
61	Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. BMC Cancer, 2018, 18, 993.	2.6	38
62	Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Science, 2018, 109, 2549-2557.	3.9	48
63	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. Neuroendocrinology, 2018, 107, 237-245.	2.5	37
64	New developments in systemic therapy for advanced biliary tract cancer. Japanese Journal of Clinical Oncology, 2018, 48, 703-711.	1.3	64
65	Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN.. Journal of Clinical Oncology, 2018, 36, 12094-12094.	1.6	9
66	Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).. Journal of Clinical Oncology, 2018, 36, 4014-4014.	1.6	4
67	MASTER KEY project: A basket/umbrella trial for rare cancers in Japan.. Journal of Clinical Oncology, 2018, 36, TPS2598-TPS2598.	1.6	3
68	Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).. Journal of Clinical Oncology, 2018, 36, 205-205.	1.6	13
69	Retrospective comparison of modified FOLFIRINOX with full-dose FOLFIRINOX for advanced pancreatic cancer: A Japanese cancer center experience.. Journal of Clinical Oncology, 2018, 36, 469-469.	1.6	3
70	Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma. Oncotarget, 2018, 9, 21086-21099.	1.8	6
71	Phase 1 studies of 3- and 6-peptide vaccine cocktail derived from GPC3, WDRPUH, and NEIL3 in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2018, 36, 387-387.	1.6	0
72	FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 polymorphism: A multicenter, retrospective study.. Journal of Clinical Oncology, 2018, 36, 484-484.	1.6	0

#	ARTICLE	IF	CITATIONS
73	An Oncogenic <i>ALK</i> Fusion and an <i>RRAS</i> Mutation in <i>KRAS</i> Mutation-Negative Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2017, 22, 158-164.	3.7	24
74	Utility of Assessing the Number of Mutated <i>KRAS</i> , <i>CDKN2A</i> , <i>TP53</i> , and <i>SMAD4</i> Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. <i>Pancreas</i> , 2017, 46, 335-340.	1.1	75
75	Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors. <i>Oncology</i> , 2017, 92, 353-359.	1.9	11
76	Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. <i>Clinical Cancer Research</i> , 2017, 23, 4625-4632.	7.0	150
77	Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 826-831.	1.3	10
78	A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 512-519.	1.3	14
79	Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1189-1196.	2.3	7
80	Mo1193 Endoscopic Covered Metal Stent Placement for Hemorrhagic Duodenal Stenosis Due to Invasion by Biliary or Pancreatic Cancer. <i>Gastrointestinal Endoscopy</i> , 2017, 85, AB457.	1.0	0
81	First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. <i>Annals of Oncology</i> , 2017, 28, v124.	1.2	4
82	Development of novel targeted therapies based on genome profiling in biliary tract cancer. <i>Annals of Oncology</i> , 2017, 28, ix50.	1.2	0
83	Comparative effectiveness of gemcitabine vs gemcitabine+nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, ix88.	1.2	2
84	Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 310-310.	1.6	3
85	Efficacy of chemotherapy in patients with recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 466-466.	1.6	1
86	Japanese Familial Pancreatic Cancer Registry with the aim to early detection of pancreatic cancer. <i>Suizo</i> , 2017, 32, 23-29.	0.1	7
87	Familial pancreatic cancer: Concept, management and issues. <i>World Journal of Gastroenterology</i> , 2017, 23, 935.	3.3	81
88	Efficacy of an educational program for patients with pancreatic and biliary cancers, and their caregivers.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18221-e18221.	1.6	0
89	Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, hv179.	1.3	7
90	C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. <i>Pancreas</i> , 2016, 45, 110-116.	1.1	37

#	ARTICLE	IF	CITATIONS
91	Clinicopathologic Features and Germline Sequence Variants in Young Patients (≤40 Years Old) With Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2016, 45, 1056-1061.	1.1	20
92	Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 385-388.	1.3	37
93	Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. <i>Cancer Cell</i> , 2016, 29, 229-240.	16.8	147
94	Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. <i>Pancreatology</i> , 2016, 16, 99-105.	1.1	25
95	A pooled analysis of long pentraxin for patients with advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 251-251.	1.6	1
96	Germline mutations in Japanese familial pancreatic cancer patients. <i>Oncotarget</i> , 2016, 7, 74227-74235.	1.8	62
97	Phase II study of fixed dose-rate gemcitabine plus S-1 as second-line treatment in advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 301-301.	1.6	0
98	Clinicopathological features and response to platinum-based chemotherapy in pancreatic neuroendocrine carcinoma: A retrospective multicenter study of 70 patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 298-298.	1.6	0
99	Clinicopathological features and response to platinum-based chemotherapy (PBC) in pancreatic neuroendocrine carcinoma (pNEC): Updated results of Japan pNEC study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15652-e15652.	1.6	0
100	Plasma biomarker for detection of early-stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-A2 isoforms.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4106-4106.	1.6	0
101	FOLFIRINOX for locally advanced or metastatic pancreatic cancer: a single institution retrospective review. <i>Annals of Oncology</i> , 2015, 26, vii120.	1.2	1
102	Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 628-633.	2.6	20
103	Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 623-627.	2.6	18
104	Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. <i>Scientific Reports</i> , 2015, 5, 18425.	3.3	164
105	Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan. <i>Journal of Gastroenterology</i> , 2015, 50, 769-775.	5.1	32
106	First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2544-2544.	1.6	1
107	Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4143-TPS4143.	1.6	4
108	Efficacy markers for cisplatin and S-1 in biliary tract carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 334-334.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Outcome and cause of death of hepatocellular carcinoma patients with extrahepatic metastases.. Journal of Clinical Oncology, 2015, 33, 456-456.	1.6	1
110	Clinicopathologic and germline mutation analysis of young patients (age 40 and younger) with pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, e15296-e15296.	1.6	0
111	Validation study of combination chemotherapy in vitro for biliary tract carcinoma.. Journal of Clinical Oncology, 2015, 33, e15115-e15115.	1.6	0
112	Current Status and Perspective of Chemotherapy for Unresectable Pancreatic Neuroendocrine Carcinoma. Annals of Oncology, 2014, 25, v18.	1.2	0
113	Gene Mutation Profile of Pancreatic Cancer in Japanese Patients and Its Association with Prognosis. Annals of Oncology, 2014, 25, v63.	1.2	0
114	A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer. BMJ Open, 2014, 4, e004352.	1.9	5
115	Japanese phase I study of <sc>GC</sc> 33, a humanized antibody against glypicanâ€³ for advanced hepatocellular carcinoma. Cancer Science, 2014, 105, 455-462.	3.9	60
116	Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Science, 2014, 105, 1176-1181.	3.9	194
117	Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Science, 2014, 105, 354-358.	3.9	9
118	Twenty-six Cases of Advanced Ampullary Adenocarcinoma Treated with Systemic Chemotherapy. Japanese Journal of Clinical Oncology, 2014, 44, 324-330.	1.3	11
119	Emerging drugs for biliary cancer. Expert Opinion on Emerging Drugs, 2014, 19, 11-24.	2.4	6
120	Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Journal of Gastroenterology, 2014, 49, 932-940.	5.1	36
121	Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2014, 32, 928-936.	2.6	5
122	Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial. BMC Cancer, 2014, 14, 301.	2.6	10
123	Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113).. Journal of Clinical Oncology, 2014, 32, TPS4149-TPS4149.	1.6	2
124	Clinical features of young patients (below age 40) with pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 199-199.	1.6	0
125	Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investigational New Drugs, 2013, 31, 1265-1274.	2.6	39
126	Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. International Journal of Clinical Oncology, 2013, 18, 207-213.	2.2	75

#	ARTICLE	IF	CITATIONS
127	Gemcitabine in Patients With Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma of the Pancreas. <i>Pancreas</i> , 2013, 42, 889-892.	1.1	6
128	Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A multicenter, open-label, phase II clinical oncology group trial (JCOG 0805). <i>Cancer Science</i> , 2013, 104, 1211-1216.	3.9	99
129	Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 739-746.	6.4	65
130	Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.. <i>Journal of Clinical Oncology</i> , 2013, 31, 231-231.	1.6	3
131	Phase I study of safety, pharmacokinetics, and efficacy of TSU-68 plus S-1 combination in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 262-262.	1.6	1
132	Current therapeutic strategy of unresectable pNET in Japan. <i>Suizo</i> , 2013, 28, 707-713.	0.1	0
133	Gemcitabine-induced Pleuropericardial Effusion in a Patient with Pancreatic Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 845-850.	1.3	12
134	Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2012, 5, 515-519.	0.7	7
135	Successful Control of Intractable Hypoglycemia Using Radiopharmaceutical Therapy with Strontium-89 in a Case with Malignant Insulinoma and Bone Metastases. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 640-645.	1.3	4
136	Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 903-911.	1.3	47
137	Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma. <i>Neuroendocrinology</i> , 2012, 96, 324-332.	2.5	48
138	Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy. <i>BMC Cancer</i> , 2012, 12, 268.	2.6	16
139	Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. <i>BMC Cancer</i> , 2012, 12, 609.	2.6	11
140	Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. <i>Pancreatology</i> , 2012, 12, 428-433.	1.1	5
141	Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 957-964.	2.3	8
142	Phase I study of TAC101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma. <i>Cancer Science</i> , 2012, 103, 1524-1530.	3.9	7
143	Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805).. <i>Journal of Clinical Oncology</i> , 2012, 30, 255-255.	1.6	3
144	Phase II study of sunitinib (SU) in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (NET).. <i>Journal of Clinical Oncology</i> , 2012, 30, 381-381.	1.6	4

#	ARTICLE	IF	CITATIONS
145	Pancreatic neuroendocrine tumors: Twenty yearsâ€™ experience of 100 patients at a single center.. Journal of Clinical Oncology, 2012, 30, 179-179.	1.6	0
146	Transarterial infusion chemotherapy with cisplatin plus S-1 for treating hepatocellular carcinoma: Results of a phase I trial.. Journal of Clinical Oncology, 2012, 30, 357-357.	1.6	0
147	Symptom changes that predict disease control by systemic chemotherapy in patients with advanced pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 195-195.	1.6	1
148	Transcatheter Arterial Infusion Chemotherapy with a Fine-powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Japanese Journal of Clinical Oncology, 2011, 41, 770-775.	1.3	28
149	Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIKâ€³33. Hepatology Research, 2011, 41, 542-552.	3.4	23
150	Phase I Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer. Journal of Immunotherapy, 2011, 34, 92-99.	2.4	91
151	Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas, 2011, 40, 415-421.	1.1	35
152	A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2011, 67, 315-324.	2.3	89
153	A Phase I/II Study of Combined Chemotherapy with Mitoxantrone and Uracil/Tegafur for Advanced Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology, 2011, 41, 328-333.	1.3	1
154	Randomized Phase II Study of Gemcitabine plus S-1 Combination Therapy vs. S-1 in Advanced Biliary Tract Cancer: Japan Clinical Oncology Group Study (JCOG0805). Japanese Journal of Clinical Oncology, 2010, 40, 1189-1191.	1.3	13
155	Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites. Japanese Journal of Clinical Oncology, 2010, 40, 1184-1188.	1.3	6
156	Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases. Oncology, 2010, 79, 39-45.	1.9	23
157	Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas. Japanese Journal of Clinical Oncology, 2010, 40, 313-318.	1.3	149
158	Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients. Clinical Pharmacokinetics, 2010, 49, 549-558.	3.5	43
159	Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?. Oncology, 2009, 77, 217-223.	1.9	28
160	Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 797-806.	1.3	55
161	Four Cases of Pancreatic Acinar Cell Carcinoma Treated with Gemcitabine or S-1 as a Single Agent. Japanese Journal of Clinical Oncology, 2009, 39, 751-755.	1.3	34
162	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 313-319.	2.3	89

#	ARTICLE	IF	CITATIONS
163	Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. <i>British Journal of Cancer</i> , 2009, 100, 870-873.	6.4	56
164	A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 683-688.	2.3	5
165	Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. <i>Gastric Cancer</i> , 2008, 11, 201-205.	5.3	22
166	Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications. <i>Journal of Gastroenterology</i> , 2008, 43, 225-232.	5.1	34
167	Liver cryptococcosis manifesting as obstructive jaundice in a young immunocompetent man: Report of a case. <i>Surgery Today</i> , 2008, 38, 271-274.	1.5	28
168	His595Tyr Polymorphism in the Methionine Synthase Reductase (MTRR) Gene Is Associated With Pancreatic Cancer Risk. <i>Gastroenterology</i> , 2008, 135, 477-488.e3.	1.3	24
169	Predictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 675-682.	1.3	17
170	DEVELOPMENT OF STRATEGIES FOR NON-SURGICAL TREATMENT IN PANCREATIC CANCER. <i>Pancreas</i> , 2008, 37, 112.	1.1	0
171	Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 755-761.	1.3	46
172	Twenty Novel Genetic Variations and Haplotype Structures of the DCK Gene Encoding Human Deoxycytidine Kinase (dCK). <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 379-384.	2.2	15
173	A Case of Gemcitabine-refractory Pancreatic Cancer Responsive to Second-line Chemotherapy Using S-1. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 973-973.	1.3	1
174	Hepatic Arterial Infusion Chemotherapy with Epirubicin in Patients with Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2007, 72, 188-193.	1.9	13
175	Phase II Study of Combination Chemotherapy with Gemcitabine and Cisplatin for Patients with Metastatic Pancreatic Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 515-520.	1.3	11
176	Analysis of Prognostic Factors Affecting Survival After Initial Recurrence and Treatment Efficacy for Recurrence in Patients Undergoing Potentially Curative Hepatectomy for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 2337-2347.	1.5	61
177	Thirty Novel Genetic Variations in the SLC29A1 Gene Encoding Human Equilibrative Nucleoside Transporter 1 (hENT1). <i>Drug Metabolism and Pharmacokinetics</i> , 2006, 21, 248-256.	2.2	31
178	Early Phase II Study of Uracilâ€“Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 552-556.	1.3	27
179	A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 756-762.	4.1	71
180	A Phase II Trial of Uracilâ€“Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 439-443.	1.3	16

#	ARTICLE	IF	CITATIONS
181	Phase I Study of Fixed Dose Rate Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 733-738.	1.3	7
182	An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer. Oncology, 2005, 68, 171-178.	1.9	110
183	Chemoradiotherapy for Locally Advanced Pancreatic Carcinoma in Elderly Patients. Oncology, 2005, 68, 432-437.	1.9	18
184	A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer. Oncology, 2005, 69, 421-427.	1.9	49
185	Phase II Study of Cisplatin, Epirubicin, and Continuous-Infusion 5-Fluorouracil for Advanced Biliary Tract Cancer. Oncology, 2003, 64, 475-476.	1.9	22
186	The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. International Journal of Clinical Oncology, 0, , .	2.2	1